Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Phosphorus containing other than solely as part of an...
Patent
1997-06-03
1998-09-08
Clardy, S. Mark
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Phosphorus containing other than solely as part of an...
514102, A61K 3166
Patent
active
058045708
ABSTRACT:
Alendronate, a bisphosphonate, when administered daily over a substantial period of time, can reduce the rate of non-vertebral fractures, in post-menopausal women.
REFERENCES:
patent: 3683080 (1972-08-01), Francis et al.
patent: 4621077 (1986-11-01), Rosini et al.
patent: 4922007 (1990-05-01), Kieczykowski et al.
patent: 5270365 (1993-12-01), Gertz et al.
patent: 5366965 (1994-11-01), Strein
patent: 5403829 (1995-04-01), Lehtinen et al.
patent: 5431920 (1995-07-01), Bechard
patent: 5462932 (1995-10-01), Brenner et al.
patent: 5616571 (1997-04-01), Daifotis et al.
Riggs, M.D., et al., "The Prevention and Treatment of Osteoporsis", The New England Journal of Medicine, 327(9), Published Aug. 27, 1992, pp. 620-627.
McClung, M.R. et al., "Alendronate Prevents or Reverse Bone Loss at the Spine & Hip in Recently Menopausal Women", J. of Bone Mineral Research, 8(Suppl. 1):S141 (1993) (Abstract Only).
Wardlaw, Ph.D., RD, "Putting Osteoporosis in Perspective", Journal of the American Dietitic Association, 93(9), Sep. 1993, pp. 1000-1006.
Balena et al., "The Effects of 2-Year Treatment With the Aminobisphosphonate Alendronate on Bone Metaboliam, Bone Histomorphometry, and Bone Strength in Ovariectomized Nonhuman Primates", The Journal of Clinical Investigation, 92(6), Published Dec. 1993, pp. 2577-2586.
Kanis et al., Osteoporosis, Blackwell Science Ltd., Oxford, U.K., pp. 170 and 173 (1994).
Riggs et al., N. Eng. J. Med., vol. 327 (1992), No. 9, pp. 620-627, "The prevention and treatment of osteopororisis".
Wardlaw, J. of Amer. Diet Assoc. 93(9), 1993, pp. 1000-1006, "Putting osteoporosis in perspective".
Balena et al., J. of Clin. Invest. 92(6), 1993, pp. 2577-2586, "The effects of 2-year treatment with the aminobisphosphonate alendronate one bone metabolism, bone histomorphometry . . . ".
McClung, M.R. et al 1993 "Alendronate Prevents or Reverses Bone Loss at the Spine and Hip in Recently Menopausal Women" J. Bon Min. Res. 8 (Supp. 11):S141 (Abstract).
Mundy, G.R. 1994 "New Drugs for Bone Diseases" Drugs of Today 30(7):589-597.
Cauley, J.A. et al 1995 "Estrogen Replacement Therapy and Fractures in Older Women" Ann. Int. Med 122 (1): 9-16.
Axelrod, D.W. et al, 1994 "Results of Long-Term Cyclical Etidronate Therapy . . . " J. Bone Min Res 9 (Supplement 1): S 136.
Fleisch, 1989 "Bisphosphonates: A New Class of Drugs in Diseases of Bone and Calcium Metabolism" Rec. Results in Cancer Res. 116: 1-28.
Rodan, G. and Balena 1993 "Bisphosphonates in the Treatment of Metabolic Bone Diseases" Ann. Med. 25: 373-378.
Fleisch 1991 "Bisphosphonates" Drugs 42(6): 919-944.
Riggs et al. 1990 "Effect of Fluoride Treatment on Fracture Rate . . . " New Eng. J. Med 322: 802-809.
Lufkin 1994 "Palmidronate: An Unrecognized Problem in Gastrointestinal Tolerability" Osteoporosis Intl 4: 320-322.
Harris, S.T. et al 1993 "Four Year Study of Intermittent Cyclic Etidronate Treatment . . . " Am J. Med. 95: 557-567.
Black, D. M. et al 1993 "Design of the Fracture Intervention Trial" Osteoporosis Intl. Suppl. 3: 529-539.
Burger, H. et al. 1994 "Vertebral Deformities as Predictors of Non-Vertebral Fractures" Brit. Med. J. 309: 991-992.
Anon "FDA Committee on Miacalcin Spray Benefits" and Etidronate Rejected by Advisory Committee Scrip No. 1979, Nov. 29, 1994 pp. 26-27.
Watts, N.B. et al 1990 "Intermittent Cyclical Etidronate Treatment of Postmenopausal Osteoporsis" New Eng J. Med 323 (2) 73-79.
Kanis, J.A. et al 1987 "Effects of Intravenous Etidronate Disodium on Skeletal and Calcium Metabolism" Am J Med. 82 (Suppl 2A): 55-70.
Storm, T. et al 1990 "Effect of Intermittent Cyclical Etidronate Therapy . . . " New Eng J Med 322(18): 1265-1271.
Heaney, R. P. et al "Etidronate Disodium in Postmenopausal Osteoporosis" Clin. Pharm. Therap. 20(5): 593-604 1976.
Gibbs, C.J. et al. 1986 "Osteomalacia in Paget's Disease . . . " Brit. Med. J. 292: 1227-1229.
Sivera, P. et al 1994 "Clinical and Haematological Improvement . . . " Br. J. Haematol. 86: 397-398.
Heany, R.P. et al 1994 "Fluoride and Osteoporsis" Ann. Int. Med. 120(8): 689-690.
Nachtigall, L. E. et al. 1979 "Estrogen Replacement Therapy I . . . " Obstet and Gynec. 53(3): 277-281.
Munk-Jensen, N. et al. 1988 "Reversal of Postmenopausal Vertebral Bone Loss by Oestrogen . . . " Br. Med. J. 296: 1150-1152.
Nordin, B. 1993 "Bone Mass, Bone Loss, Bone Density and Fractures" (Suppl.): S1-7.
Karpf David B.
Polvino William J.
Santora, II Arthur C.
Shapiro Deborah Ruth
Thompson Desmond E.
Clardy S. Mark
Giesser Joanne M.
Harrison Robert H.
Merck & Co. , Inc.
Sabatelli Anthony D.
LandOfFree
Method of lessening the risk of non-vertebral bone fractures does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of lessening the risk of non-vertebral bone fractures, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of lessening the risk of non-vertebral bone fractures will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1282303